Theranexus SA logo

ALTHX - Theranexus SA News Story

€3.45 0.3  8.0%

Last Trade - 21/01/22

Sector
Healthcare
Size
Micro Cap
Market Cap £13.2m
Enterprise Value £6.58m
Revenue £n/a
Position in Universe 737th / 851

BRIEF-Theranexus: Success Of Phase 2 Study For THN102

Tue 31st March, 2020 5:18pm
March 31 (Reuters) - THERANEXUS SA  ALTHX.PA :
    * SUCCESS OF ITS PHASE 2 STUDY FOR THN102 IN THE PARKINSON
DISEASE
    * THN102 MEETS PRIMARY ENDPOINT
    * THN102: EXCELLENT TOLERANCE IN PARKINSON'S DISEASE
PATIENTS

Source text for Eikon:  ID:nACT62757 
Further company coverage:  ALTHX.PA 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
© Stockopedia 2022, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.